US FDA extends review of Novo Nordisk's hemophilia drug over facility issues The US FDA has extende...
US FDA extends review of Novo Nordisk's hemophilia drug over facility issues The US FDA has extended its review of Novo Nordisk's experimental hemophilia A drug due to ongoing remediation work at a manufacturing facility, the Danish drugmaker said on Friday.